Vernalis PLC Regulatory News (VER)

2 March 2012

Vernalis plc ("the Company")

Voting Rights and Capital

Following admission of the New Ordinary Shares, issued in connection with the Firm Placing and Placing and Open Offer announced on 10 February 2012, the Company's issued share capital as at 2 March 2012 consists of 442,112,768 Ordinary Shares of 1 pence each with voting rights. No shares are held in treasury. Therefore, the total number of voting rights in the Company is 442,112,768.

The above figure of 442,112,768 may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the FSA's Disclosure and Transparency Rules.

Invesco Asset Management Limited holds 189,675,214 Ordinary Shares of 1 pence each (representing approximately 42.90 per cent. of the issued ordinary share capital of the Company).

Please note that the ISIN for Vernalis plc (LSE: VER) Ordinary Shares has not changed from GB00B3Y5L754.

About Vernalis:

Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, and eight candidates in development, seven of which are designated priority programmes. Four of these priority development programmes are currently unpartnered and three are partnered. Pipeline programmes are derived from both our own research activities where we have significant expertise in fragment and structure based drug discovery, as well as from collaborations. Our technologies, capabilities and products are endorsed by collaborations with Endo, Genentech, GSK, Lundbeck, Menarini, Novartis and Servier.

For further information about Vernalis, please visit www.vernalis.com